Combination treatment for advanced prostate cancer after first-line therapy
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug combination for men with advanced prostate cancer that has stopped responding to initial hormone therapy. The treatment targets low-oxygen areas in tumors, which may help slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your prostate cancer has spread to other parts of the body (stage M1).
- Your cancer has progressed despite treatment with one of these drugs: abiraterone, enzalutamide, darolutamide, or apalutamide, and you have either received chemotherapy (docetaxel) or cannot have it.
- You are on ongoing hormone therapy (like LHRH agonists or antagonists) and your testosterone level is below 50 ng/dL.
- You are generally able to care for yourself (ECOG performance status 0-2).
- If you have lung disease, you must have adequate oxygen levels after a short walk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination therapy for men with advanced prostate cancer that has stopped responding to hormone treatment. The goal is to see if this treatment can shrink tumors or slow down the cancer, and it may offer a new option when standard treatments have not worked.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
This trial tests a new combination of three drugs—evofosfamide, zalifrelimab, and balstilimab—in people with advanced prostate, pancreatic, or certain head and neck cancers that have stopped responding to standard treatments.
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This trial combines radiation therapy with two drugs (fluzopanib and abiraterone acetate) to treat men with metastatic castration-resistant prostate cancer that hasn't been treated yet. The goal is to see if this triple approach helps slow the cancer's growth.
Hear when a new Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.